257 related articles for article (PubMed ID: 22237658)
21. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer.
Lan YQ; Wu RP; Huang XB; Wang XL; Zhong DT; Huang CY; Song JT
Tumori; 2018; 104(1):22-29. PubMed ID: 28777427
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
23. [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Wang ZH; Guo J; Chen Z; Li CZ; Sheng LJ; Zhou DG; Liu B; Liu J; Wang QC; Zhang EN
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):389-91. PubMed ID: 18953843
[TBL] [Abstract][Full Text] [Related]
24. [Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
Li J; Lu M; Shen L; Zhang XD; Li Y
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):933-6. PubMed ID: 20193337
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Louvet C; André T; Tigaud JM; Gamelin E; Douillard JY; Brunet R; François E; Jacob JH; Levoir D; Taamma A; Rougier P; Cvitkovic E; de Gramont A
J Clin Oncol; 2002 Dec; 20(23):4543-8. PubMed ID: 12454110
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.
Xiang XJ; Liu YW; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
Anticancer Drugs; 2012 Jun; 23(5):561-6. PubMed ID: 22481063
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
Zhao JG; Qiu F; Xiong JP; Zhang L; Xiang XJ; Yu F; Yan J; Zhan ZY; Feng M
Anticancer Drugs; 2009 Apr; 20(4):281-6. PubMed ID: 19247179
[TBL] [Abstract][Full Text] [Related]
30. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
31. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
[TBL] [Abstract][Full Text] [Related]
33. [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Lou F; Zhu YH; Pan HM
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):75-8. PubMed ID: 19538878
[TBL] [Abstract][Full Text] [Related]
34. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Goldberg RM; Tabah-Fisch I; Bleiberg H; de Gramont A; Tournigand C; Andre T; Rothenberg ML; Green E; Sargent DJ
J Clin Oncol; 2006 Sep; 24(25):4085-91. PubMed ID: 16943526
[TBL] [Abstract][Full Text] [Related]
35. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
Zhang XL; Shi HJ; Cui SZ; Tang YQ; Ba MC
Eur J Surg Oncol; 2011 Jun; 37(6):466-72. PubMed ID: 21414740
[TBL] [Abstract][Full Text] [Related]
36. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.
Malka D; François E; Penault-Llorca F; Castan F; Bouché O; Bennouna J; Ghiringhelli F; de la Fouchardière C; Borg C; Samalin E; Bachet JB; Raoul JL; Miglianico L; Bengrine-Lefèvre L; Dahan L; Lecaille C; Aparicio T; Stanbury T; Perrier H; Cayre A; Laurent-Puig P; Gourgou S; Emile JF; Taïeb J
Eur J Cancer; 2019 Jul; 115():97-106. PubMed ID: 31129386
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis.
Kang SH; Min SH; Kim JW; Lee E; Park SW; Lee S; Oh HJ; Park YS; Lee YJ; Kim JW; Ahn SH; Suh YS; Lee KW; Lee HS; Kim HH
Ann Surg Oncol; 2022 Aug; 29(8):5084-5091. PubMed ID: 35322307
[TBL] [Abstract][Full Text] [Related]
38. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
[TBL] [Abstract][Full Text] [Related]
39. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
40. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]